Curetis Announces Change of the Composition of Its Supervisory Board
in portfolio news
- Dr. Holger Reithinger resigns as member of the Supervisory Board
- Company exploring options to further evolve Board at upcoming 2018 AGM
Curetis N.V. (the "Company" and, together with Curetis GmbH and Curetis USA Inc., "Curetis"), a developer of next-level molecular diagnostic solutions, today announced that Dr. Holger Reithinger, General Partner at Forbion, resigns from Curetis’ Supervisory Board effective today, April 30, 2018.
Dr. Reithinger has served on the Supervisory Board of Curetis N.V. since the IPO in November 2015. Previously, he had already served on the Supervisory Board of the predecessor company, Curetis AG, to which he had been elected in 2011 to represent Forbion, one of the first venture capital companies that invested in Curetis. Following the recent PIPE financing, Forbion currently holds about 8.7% of Curetis’ share capital.
After Dr. Reithinger’s resignation, the Supervisory Board consists of six members: William E. Rhodes, III. (Chairman of the Supervisory Board), Mario Crovetto, Dr. Werner Schaefer, Dr. Prabha Fernandes, Dr. Rudy DeKeyser, and Dr. med. Nils Clausnitzer who had been elected at the last AGM in 2017 to further strengthen the Supervisory Board.
“Holger has been a very engaged Supervisory Board colleague who very actively supported the Company with his broad network in the industry. On behalf of the Supervisory Board, I would like to thank Holger for his many years of strong support and dedication to the Company,” commented William E. Rhodes, Chairman of the Curetis N.V. Supervisory Board. “While we believe that with the remaining six members the Supervisory Board is still very balanced, the Board is also exploring options to use Holger’s resignation as an opportunity to further evolve the composition of the Board at the upcoming 2018 Annual General Shareholder Meeting.”
“On behalf of the entire Curetis Management Team, I would like to sincerely thank Holger for his invaluable support and continuous guidance and advice over many years, which has helped develop Curetis from a small, R&D-driven company to a publicly listed, fully integrated, commercial-stage molecular diagnostics enterprise with a global presence,” said Oliver Schacht, PhD, CEO of Curetis N.V.